1-20 of 35
glimepiride
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial

Yumie Takeshita, Masao Honda, Kenichi Harada, Yuki Kita, Noboru Takata, Hiromasa Tsujiguchi, Takeo Tanaka, Hisanori Goto, Yujiro Nakano, Noriho Iida, Kuniaki Arai, Tatsuya Yamashita, Eishiro Mizukoshi, Hiroyuki Nakamura, Shuichi Kaneko, Toshinari Takamura
Journal: Diabetes Care
Diabetes Care 2022;45(9):2064–2075
https://doi.org/10.2337/dc21-2049
Published: 27 July 2022
View article titled, Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial
Open the PDF for Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial in another window
Journal Articles

Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA)

Alexander S. Christensen, Sofie Hædersdal, Julie Støy, Heidi Storgaard, Ulla Kampmann, Julie L. Forman, Marta Seghieri, Jens J. Holst, Torben Hansen, Filip K. Knop, Tina Vilsbøll
Journal: Diabetes Care
Diabetes Care 2020;43(9):2025–2033
https://doi.org/10.2337/dc20-0408
Published: 13 July 2020
View article titled, Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA)
Open the PDF for Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA) in another window
Journal Articles

A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm

Matthew C. Riddle
Journal: Diabetes Care
Diabetes Care 2019;42(12):2161–2163
https://doi.org/10.2337/dci19-0034
Published: 12 November 2019
View article titled, A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm
Open the PDF for A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm in another window
Journal Articles

Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride

Elisabetta Patorno, Sebastian Schneeweiss, Chandrasekar Gopalakrishnan, David Martin, Jessica M. Franklin
Journal: Diabetes Care
Diabetes Care 2019;42(12):2204–2210
https://doi.org/10.2337/dc19-0069
Published: 11 July 2019
View article titled, Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride
Open the PDF for Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride in another window
Includes: Supplementary data
Journal Articles

Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride

Sven Kohler, Stefan Kaspers, Afshin Salsali, Cordula Zeller, Hans J. Woerle
Journal: Diabetes Care
Diabetes Care 2018;41(8):1809–1816
https://doi.org/10.2337/dc17-1525
Published: 15 June 2018
View article titled, Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride
Open the PDF for Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride in another window
Includes: Supplementary data
Journal Articles

Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia

Charles E. Leonard, Colleen M. Brensinger, Christina L. Aquilante, Warren B. Bilker, Denise M. Boudreau, Rajat Deo, James H. Flory, Joshua J. Gagne, Margaret J. Mangaali, Sean Hennessy
Journal: Diabetes Care
Diabetes Care 2018;41(4):713–722
https://doi.org/10.2337/dc17-0294
Published: 02 February 2018
View article titled, Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia
Open the PDF for Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia in another window
Includes: Supplementary data
Journal Articles

Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events

Antonios Douros, Hui Yin, Oriana Hoi Yun Yu, Kristian B. Filion, Laurent Azoulay, Samy Suissa
Journal: Diabetes Care
Diabetes Care 2017;40(11):1506–1513
https://doi.org/10.2337/dc17-0595
Published: 01 September 2017
View article titled, Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events
Open the PDF for Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)

Francesco Giorgino, Marian Benroubi, Jui-Hung Sun, Alan G. Zimmermann, Valeria Pechtner
Journal: Diabetes Care
Diabetes Care 2015;38(12):2241–2249
https://doi.org/10.2337/dc14-1625
Published: 18 June 2015
View article titled, Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
Open the PDF for Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2) in another window
Includes: Supplementary data
Journal Articles

Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial

Markku Laakso, Julio Rosenstock, Per-Henrik Groop, Anthony H. Barnett, Baptist Gallwitz, Uwe Hehnke, Ilkka Tamminen, Sanjay Patel, Maximilian von Eynatten, Hans-Juergen Woerle
Journal: Diabetes Care
Diabetes Care 2015;38(2):e15–e17
https://doi.org/10.2337/dc14-1684
Published: 10 January 2015
View article titled, Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial
Open the PDF for Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial in another window
Journal Articles

Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study

Lawrence A. Leiter, Kun-Ho Yoon, Pablo Arias, Gisle Langslet, John Xie, Dainius A. Balis, Dawn Millington, Frank Vercruysse, William Canovatchel, Gary Meininger
Journal: Diabetes Care
Diabetes Care 2015;38(3):355–364
https://doi.org/10.2337/dc13-2762
Published: 09 September 2014
View article titled, Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study
Open the PDF for Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study in another window
Includes: Supplementary data
Journal Articles

Effect of Exenatide, Sitagliptin, or Glimepiride on β-Cell Secretory Capacity in Early Type 2 Diabetes

Lalitha Gudipaty, Nora K. Rosenfeld, Carissa S. Fuller, Robert Gallop, Mark H. Schutta, Michael R. Rickels
Journal: Diabetes Care
Diabetes Care 2014;37(9):2451–2458
https://doi.org/10.2337/dc14-0398
Published: 07 August 2014
View article titled, Effect of Exenatide, Sitagliptin, or Glimepiride on β-Cell Secretory Capacity in Early Type 2 Diabetes
Open the PDF for Effect of Exenatide, Sitagliptin, or Glimepiride on β-Cell Secretory Capacity in Early Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

Bo Ahrén, Susan L. Johnson, Murray Stewart, Deborah T. Cirkel, Fred Yang, Caroline Perry, Mark N. Feinglos
Journal: Diabetes Care
Diabetes Care 2014;37(8):2141–2148
https://doi.org/10.2337/dc14-0024
Published: 12 July 2014
View article titled, HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
Open the PDF for HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin in another window
Includes: Supplementary data
Journal Articles

Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist: A Double-Blind, Randomized, Crossover Trial

Signe H. Østoft, Jonatan I. Bagger, Torben Hansen, Oluf Pedersen, Jens Faber, Jens J. Holst, Filip K. Knop, Tina Vilsbøll
Journal: Diabetes Care
Diabetes Care 2014;37(7):1797–1805
https://doi.org/10.2337/dc13-3007
Published: 12 June 2014
View article titled, Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist: A Double-Blind, Randomized, Crossover Trial
Open the PDF for Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist: A Double-Blind, Randomized, Crossover Trial in another window
Includes: Supplementary data
Journal Articles

C-Peptide Levels in Latent Autoimmune Diabetes in Adults Treated With Linagliptin Versus Glimepiride: Exploratory Results From a 2-Year Double-Blind, Randomized, Controlled Study

Odd Erik Johansen, Bernhard O. Boehm, Valdemar Grill, Peter A. Torjesen, Sudipta Bhattacharya, Sanjay Patel, Kristiane Wetzel, Hans-Juergen Woerle
Journal: Diabetes Care
Diabetes Care 2014;37(1):e11–e12
https://doi.org/10.2337/dc13-1523
Published: 11 December 2013
View article titled, C-Peptide Levels in Latent Autoimmune Diabetes in Adults Treated With Linagliptin Versus Glimepiride: Exploratory Results From a 2-Year Double-Blind, Randomized, Controlled Study
Open the PDF for C-Peptide Levels in Latent Autoimmune Diabetes in Adults Treated With Linagliptin Versus Glimepiride: Exploratory Results From a 2-Year Double-Blind, Randomized, Controlled Study in another window
Journal Articles

Randomized, Double-Blind, Dose-Ranging Study of TAK-875, a Novel GPR40 Agonist, in Japanese Patients With Inadequately Controlled Type 2 Diabetes

Kohei Kaku, MD, Takahiro Araki, MD, Ryoji Yoshinaka, BENG
Journal: Diabetes Care
Diabetes Care 2013;36(2):245–250
https://doi.org/10.2337/dc12-0872
Published: 17 January 2013
View article titled, Randomized, Double-Blind, Dose-Ranging Study of TAK-875, a Novel GPR40 Agonist, in Japanese Patients With Inadequately Controlled Type 2 Diabetes
Open the PDF for Randomized, Double-Blind, Dose-Ranging Study of TAK-875, a Novel GPR40 Agonist, in Japanese Patients With Inadequately Controlled Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Glimepiride-Induced Bronchial Asthma: Case report

Kazuhisa Tsukamoto, MD, PHD, Keisuke Ohta, MD, Ryo Suzuki, MD, PHD, Masumi Hara, MD, PHD, Jun-ichi Osuga, MD, PHD, Kazuyuki Tobe, MD, PHD, Takashi Kadowaki, MD, PHD
Journal: Diabetes Care
Diabetes Care 2008;31(12):e91
https://doi.org/10.2337/dc08-1536
Published: 01 December 2008
View article titled, Glimepiride-Induced Bronchial Asthma: <subtitle>Case report</subtitle>
Open the PDF for Glimepiride-Induced Bronchial Asthma: <subtitle>Case report</subtitle> in another window
Journal Articles

Glimepiride Versus Metformin as Monotherapy in Pediatric Patients With Type 2 Diabetes: A randomized, single-blind comparative study

Michael Gottschalk, MD, Thomas Danne, MD, Aleksandra Vlajnic, MD, José F. Cara, MD
Journal: Diabetes Care
Diabetes Care 2007;30(4):790–794
https://doi.org/10.2337/dc06-1554
Published: 01 April 2007
View article titled, Glimepiride Versus Metformin as Monotherapy in Pediatric Patients With Type 2 Diabetes: <subtitle>A randomized, single-blind comparative study</subtitle>
Open the PDF for Glimepiride Versus Metformin as Monotherapy in Pediatric Patients With Type 2 Diabetes: <subtitle>A randomized, single-blind comparative study</subtitle> in another window
Journal Articles

Good Glycemic Control With Flexibility in Timing of Basal Insulin Supply : A 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride

Eberhard Standl, MD, Stephan Maxeiner, MD, Sotirios Raptis, MD (HON), Zahra Karimi-Anderesi, MD, Matthias Axel Schweitzer, MD, the HOE901/4009 Study Group
Journal: Diabetes Care
Diabetes Care 2005;28(2):419–420
https://doi.org/10.2337/diacare.28.2.419
Published: 01 February 2005
View article titled, Good Glycemic Control With Flexibility in Timing of Basal Insulin Supply : <subtitle>A 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride</subtitle>
Open the PDF for Good Glycemic Control With Flexibility in Timing of Basal Insulin Supply : <subtitle>A 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride</subtitle> in another window
Journal Articles

Comparison of Basal Insulin Added to Oral Agents Versus Twice-Daily Premixed Insulin as Initial Insulin Therapy for Type 2 Diabetes

Hans U. Janka, MD, Gerd Plewe, MD, Matthew C. Riddle, MD, Christine Kliebe-Frisch, PHD, Matthias A. Schweitzer, MD, Hannele Yki-Järvinen, MD
Journal: Diabetes Care
Diabetes Care 2005;28(2):254–259
https://doi.org/10.2337/diacare.28.2.254
Published: 01 February 2005
View article titled, Comparison of Basal Insulin Added to Oral Agents Versus Twice-Daily Premixed Insulin as Initial Insulin Therapy for Type 2 Diabetes
Open the PDF for Comparison of Basal Insulin Added to Oral Agents Versus Twice-Daily Premixed Insulin as Initial Insulin Therapy for Type 2 Diabetes in another window
Journal Articles

The Efficacy and Safety of Glimepiride in the Management of Type 2 Diabetes in Muslim Patients During Ramadan

the Glimepiride in Ramadan (GLIRA) Study Group
Journal: Diabetes Care
Diabetes Care 2005;28(2):421–422
https://doi.org/10.2337/diacare.28.2.421
Published: 01 February 2005
View article titled, The Efficacy and Safety of Glimepiride in the Management of Type 2 Diabetes in Muslim Patients During Ramadan
Open the PDF for The Efficacy and Safety of Glimepiride in the Management of Type 2 Diabetes in Muslim Patients During Ramadan in another window